BFM
CTNM

Boothbay Fund Management’s Contineum Therapeutics CTNM Stock Holding History

Boothbay Fund Management’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.64M Hold
222,329
– – 0.05% 447
2026
Q1 		$2.9M Buy
222,329
+149,835
+207% +$2.01M 0.04% 488
2025
Q4 		$829K Buy
+72,494
New +$827K 0.01% 873

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Boothbay Fund Management's CTNM Position: Q2 2026 in Review

Boothbay Fund Management held its Contineum Therapeutics (CTNM) position steady in Q2 2026 at 222,329 shares worth $3.64M. The position accounts for 0.05% of the portfolio, ranked #447.

Boothbay Fund Management first reported a position in CTNM in Q4 2025 and has held it in 3 quarters since. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • Boothbay Fund Management held 222,329 shares of Contineum Therapeutics worth $3.64M as of Q2 2026.
  • Boothbay Fund Management left its Contineum Therapeutics share count unchanged in Q2 2026.
  • Contineum Therapeutics made up 0.05% of Boothbay Fund Management's portfolio in Q2 2026, its #447 holding.
  • Boothbay Fund Management first reported a position in Contineum Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.